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The Scale for the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of
Negative Symptoms (SANS), and the Positive and Negative Syndrome Scale for Schizophrenia
(PANSS) are the most widely used schizophrenia symptom rating scales, but despite their co-
existence for 25 years no easily usable between-scale conversion mechanism exists. The aim of
this study was to provide equations for between-scale symptom rating conversions. Two- hundred-
and-five schizophrenia patients [mean age±SD=39.5±11.6), 156 males] were assessed with the
SANS, SAPS, and PANSS. Pearson’s correlations between symptom scores from each of the
scales were computed. Linear regression analyses, on data from 176 randomly selected patients,
were performed to derive equations for converting ratings between the scales. Intraclass
correlations, on data from the remaining 29 patients, not part of the regression analyses, were
performed to determine rating conversion accuracy. Between-scale positive and negative symptom
ratings were highly correlated. Intraclass correlations between the original positive and negative
symptom ratings and those obtained via conversion of alternative ratings using the conversion
equations were moderate to high (ICCs = 0.65 to 0.91). Regression-based equations may be useful
for conversion between schizophrenia symptom severity as measured by the SANS/SAPS and
PANSS, though additional validation is warranted. This study’s conversion equations,
implemented at http::/converteasy.org, may aid in the comparison of medication efficacy studies,
in meta- and mega-analyses examining symptoms as moderator variables, and in retrospective
combination of symptom data in multi-center data sharing projects that need to pool symptom
rating data when such data are obtained using different scales.
Keywords
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1. Introduction
The Scale for the Assessment of Positive Symptoms [SAPS(Andreasen, 1984)], Scale for
the Assessment of Negative Symptoms [SANS(Andreasen, 1983)], and the Positive And
Negative Syndrome Scale [PANSS(Kay et al., 1987; Kay et al., 1989)] are the most widely
used symptom rating scales in schizophrenia research. Yet, despite their co-existence for 25
years, no equations for the conversion of scores between the scales exist. Such equations can
be useful when examining treatment efficacy across studies, when conducting meta- and
mega-analyses, and when sharing data sets in which different symptom ratings scales were
used.
Numerous factor analysis studies on schizophrenia symptom ratings confirm the existence of
negative, positive and disorganized syndrome constructs for the SAPS/SANS (Arndt et al.,
1991; Arndt et al., 1995) and the PANSS (Marder et al., 1997). Additionally, recent work
confirmed a more complex five factor syndrome model of the PANSS, including positive,
negative, disorganization, excitement, and emotional distress syndrome dimensions (van der
Gaag et al., 2006), though it has been argued that further validation of these syndromes with
other aspects of schizophrenia is warranted (Mortimer, 2007). Symptom constructs remain
useful as they appear to have differential prediction value with regard to functioning in
patients with schizophrenia (Ventura et al., 2009) as well as those at clinical-high-risk for
psychosis (Fulford et al., 2013). Moreover, lack of adequate treatment for negative
symptoms make them a clinically relevant investigation topic (Kirkpatrick et al., 2006).
Though the PANSS has several psychometric advances over other schizophrenia symptom
rating scales –e.g., the PANSS has the same number of items for the positive and negative
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symptom dimensions, such that the preponderance of either of these symptoms can be
assessed (Kay, 1990)– the NIMH consensus statement on negative symptoms suggests that
the SANS is an appropriate scale for negative symptom measurement, while PANSS may
also be used (Kirkpatrick et al., 2006). The SANS and SAPS include positive and negative
symptom sub domains, respectively, as well as additional details such as the hallucination
modality specified in the SAPS. Cursory review of the literature shows that either the
PANSS or the SANS/SAPS are used across studies, complicating cross-study comparisons.
A few studies have examined how the SANS/SAPS and PANSS relate to each other (Lyne
et al., 2011; Norman et al., 1996; Rabany et al., 2011). Norman and colleagues (Norman et
al., 1996) reported higher between scale correlations when using the average of multiple
raters (r=0.88-0.91) than when using scores from different raters (r=0.58-0.81); though no
statistical comparisons were performed. Rabany and colleagues (Rabany et al., 2011)
observed a moderate Spearman’s rank correlation between the PANSS-Negative subscale
and the SANS (r=0.56) though they concluded that the scales measure similar constructs.
Lyne and colleagues (2011) reported correlations between SAPS/SANS and PANSS in the
range of 0.58-0.91 across studies (Lyne et al., 2011). Importantly, they described 3 methods
for combining symptom scales in collaborative projects by: (1) comparing scale scores with
external clinical outcome, (2) recoding global scores as categories of severity, and (3)
creating remission criteria (Lyne et al., 2011); the latter possibly presenting advantages in
outcome research (Mortimer, 2007). Though useful, the proposed methods result in the loss
of much of the quantitative symptom rating information that is particularly important for the
comparison of treatment efficacy and for using symptom severity as moderator variables in
meta- or mega-analyses. To our knowledge, no study has examined the use of regression
equations to convert symptom ratings from one scale to another; a method that has been
successfully applied in motor rating scales in Parkinson’s Disease (Verbaan et al., 2011).
In Phase 3 of the Function Bioinformatics Research Network (FBIRN) multi-center imaging
project, clinicians rated positive and negative symptoms using both SAPS/SANS and
PANSS on all the patients with schizophrenia who participated in the study. In this report,
we explore the feasibility of using regression equations for converting symptom ratings
between scales. The aim of this study is to provide conversion equations and conversion
score reliabilities for SAPS/SANS and PANSS ratings. The regression-based equations
derived may facilitate the interpretation of treatment effects on symptom improvement
across studies, symptom rating scale conversions in meta- and mega-analyses, as well as the
sharing of retrospectively collected data sets.
2. Materials and Methods
2.1. Participants
Schizophrenia patients (n=205, mean age±SD=39.5.±11.6, 156 [76%] males), recruited from
7 sites, participated in Phase 3 of the Function Biomedical Informatics Research Network
(FBIRN) fMRI study (Table 1). Schizophrenia diagnosis was confirmed by the Structured
Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I/P(First et al., 2002)) and all
patients were clinically stable on antipsychotic medication for at least two months. The
study excluded patients with schizoaffective disorder, and schizophrenia patients with a
history of major medical illness, contraindications for MRI, insufficient eyesight to see with
normal acuity with MRI compatible corrective lenses, a history of drug dependence in the
last 5 years or a current substance abuse disorder, an IQ less than 75, or significant
extrapyramidal symptoms. Clinical severity assessments included the Scale for the
Assessment of Positive Symptoms (SAPS(Andreasen, 1984)), the Scale for the Assessment
of Negative Symptoms (SANS(Andreasen, 1983)), the Positive and Negative Syndrome
Scale (PANSS(Kay et al., 1989)), the Premorbid Adjustment Scale (PAS(Cannon-Spoor et
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al., 1982)), the Calgary Depression Scale (CDS(Addington et al., 1990)), and the Clinical
Global Impression (CGI(Guy, 1976)). Symptom ratings were based on the past month.
Patients were also assessed with the Hollingstead Socioeconomic Status Scale
(HSSS(Hollingstead, 1975)), the Edinburgh Handedness Questionnaire (EDQ(Oldfield,
1971)), the Fagerstrom-Lifetime Smoking Form (Fagerstrom, 1978), a basic demographics
form, and the North American Adult Reading Test (NAART(Uttl, 2002)). The sample
included 146 paranoid, 7 disorganized, 36 undifferentiated, and 16 residual subtype; 188
right-, 13 left-, and 4 bilateral-handed; and 4 American Indian or Alaskan Native, 22 Asian,
43 Black or African American, 3 Native Hawaiian or Pacific Islander, and 133 White
patients. Ratings were standardized across sites through cross-site group training sessions
with experienced clinical raters and by rating videotapes from several patients for
comparisons with expert assessments.
Written informed consent, including permission to share de-identified data between the
centers and with the wider research community, approved by the University of California
Irvine, the University of California Los Angeles, the University of California San Francisco,
Duke University, University of North Carolina, University of New Mexico, University of
Iowa, and University of Minnesota Institutional Review Boards, was obtained from all study
participants.
2.2. Symptom Rating Scores
The following formulas calculated the negative and positive symptom scores: (1) SANS
Total (Composite) score = sum(of SANS items 1-7, 9-12, 14-16, 18-21, and 23-24), (2)
SAPS Total (Composite) score = sum(of SAPS items 1-6, 8-19, 21-24, and 26-33), (3)
SANS (Global) Summary score = sum(of SANS items 8, 13, 17, 22, and 25, which include
affective flattening, alogia, avolition, anhedonia, and attention global rating scores,
respectively), (4) SAPS (Global) Summary score = sum(of SAPS items 7, 20, 25, and 34,
which include hallucinations, delusions, bizarre behavior, and thought disorder global rating
scores, respectively), (5) PANSS Positive = sum(of PANSS items 1-7), (6) PANSS Negative
= sum(of PANSS items 8-15), (7) Marder Positive Symptom Factor Score (Marder Positive)
= sum(of PANSS items 1, 3, 5-6, 14-15, 23, and 26), and (8) Marder Negative Symptom
Factor Score (Marder Negative) = sum(of PANSS items 8-11 and 13). Note that the PANSS
ratings that make up the Marder Factor scores are equally weighted as in the original
publication (Marder et al., 1997). For additional descriptions of the SAPS, SANS, and
PANSS see Supplement S1.
2.3. Statistical Analyses
Pearson’s correlations among positive and negative symptom scores were computed based
on the overall sample (SAS PROC CORR, Statistical Analysis Software, Version 9.2, SAS
Institute Inc., Cary, NC, USA). Regression analyses predicting the SAPS scores with the
PANSS Positive score, SANS scores with PANSS Negative score, and SAPS and SANS
Summary with their respective Global scores, as well as each of these scores with their
corresponding Marder Symptom Factor scores, were performed on data from 176 patients
randomly selected from the overall sample (SAS PROC MIXED, Statistical Analysis
Software, Version 9.2, SAS Institute Inc., Cary, NC, USA). Intraclass correlations (ICCs;
and their confidence intervals) between symptom rating scores and the same symptom
scores predicted by alternative symptom rating scores, based on the regression equations,
were computed on data from the remaining 29 patients, not part of the regression analyses.
Based on estimates in the R ICC package, this sample size allows for determining significant
ICCs larger than 0.54 (i.e., excluding 0 from their confidence intervals), while maintaining
the largest possible sample to compute the regression equations. We computed one-way
random, absolute agreement ICCs using the R (Version 2.7.0) irr package. ICCs can be
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interpreted as excellent (> 0.8), good (0.7 - 0.8), fair (0.5 - 0.7) or poor (< 0.5) (American
Psychiatric Association, 2000). R-squared differences between the original regression model
and the (validation) model predicting symptom ratings with predicted symptom scores are
reported in a supplementary table S1.
3. Results
3.1. Correlations
The various positive and negative symptom scores derived from the PANSS, SANS, and
SAPS, were highly correlated with each other (see Table 2).
3.2. Symptom Ratings Conversion Equations
The following sections present the equations to convert between the positive and negative
symptom scores provided by the SAPS, SANS, and PANSS based on the linear regression
analyses (see Figures 1 and 2 and Figures 1S-10S in Supplement S1 for associated
regression plots). The equations are implemented at http://converteasy.org for use by the
scientific community.
3.2.1. Positive Symptom Ratings Conversion Equations
3.2.1.1 Between SAPS and PANSS: SAPS [composite] Total score = −14.5359 + (2.3771
* PANSS Positive) (1)
PANSS Positive = 11.1886 + (0.2587 * SAPS [composite] Total score) (2)
SAPS [global] Summary score = −3.222 + (0.567 * PANSS Positive) (3)
PANSS Positive = 9.3264 + (1.1072 * SAPS [global] Summary score) (4)
3.2.1.2 Within SAPS: SAPS [composite] Total score = 0.2941 + (2.9298 * SAPS [global]
Summary score) (5)
SAPS [global] Summary score = 2.3526 + (0.1932 * SAPS [composite] Total score) (6)
3.2.1.3 Between PANSS/SAPS and Marder: Marder Positive = 1.0747+ (1.0743 *
PANSS Positive) (7) PANSS Positive = 1.783 + (0.7735 * Marder Positive) (8)
Marder Positive = 12.6431 + (0.3052 * SAPS [composite] Total score) (9)
SAPS [composite] Total score = −13.6542 + (1.7071 * Marder Positive) (10)
Marder Positive = 10.6275 + (1.2736 * SAPS [global] Summary score) (11)
SAPS [global] Summary score = −2.7599 + (0.4696 * Marder Positive) (12)
3.2.2. Negative Symptom Ratings Conversion Formulas
3.2.2.1 Between SANS and PANSS: SANS [composite] Total score = −8.376 + (2.1002 *
PANSS Negative) (13)
PANSS Negative = 7.1196 + (0.3362 * SANS [composite] Total score) (14)
SANS [global] Summary score = −2.0671 + (0.665 * PANSS Negative) (15)
PANSS Negative = 6.7515 + (1.0287 * SANS [global] Summary score) (16)
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3.2.2.2 Within SANS: SANS [composite] Total score = 0.565 + (2.8434* SANS [global]
Summary score) (17)
SANS [global] Summary score = 1.0863 + (0.2943 * SANS [composite] Total score) (18)
3.2.2.3 Between PANSS/SAPS and Marder: Marder Negative = −0.6095 + (1.0209 *
PANSS Negative) (19)
PANSS Negative = 2.6381 + (0.8373 * Marder Negative) (20)
Marder Negative = 5.9723 + (0.3758 * SANS [composite] Total score) (21)
SANS [composite] Total score = −5.4065 + (1.9319 * Marder Negative) (22)
Marder Negative = 5.8548 + (1.0209 * SANS [global] Summary score) (23)
SANS [global] Summary score = 2.6381 + (0.8373 * Marder Negative) (24)
3.3. Reliability of Predicted Ratings
Intra-class Correlations (95% CI) Between Measured and Predicted Symptom Ratings based
on Conversion Formulas are in the range of 0.65-0.97 (see Table 3). The increase in mean
squared prediction error between the original regression and the validation regression is on
average 17% and 3% for the positive and negative symptoms, respectively (see Table 4 in
Supplement S1).
Discussion
The main findings from the study are that (1) the SANS and PANSS negative symptom
ratings and SAPS and PANSS positive symptom ratings are highly correlated
(r205=0.71-0.84) in our large sample of patients with schizophrenia and that (2) linear
regression-based conversion formulas may be useful for converting symptom dimension
scores between these widely used scales.
The observed high correlation between SANS and PANSS negative symptom ratings
(r205=0.71-0.84) is consistent with prior findings of moderate to high correlations between
these scales (Lyne et al., 2011; Rabany et al., 2011), in particular when mean or same rater
ratings are used (Norman et al., 1996), and indicates that both scales measure largely similar
constructs. The correlations between the SAPS and PANSS positive symptoms
(r205=0.71-0.78) appear a little bit lower than those for the negative symptoms
(r205=0.82-0.84), which could be due either to the inclusion of positive and disorganized
symptom items in the SAPS (Andreasen and Olsen, 1982) not present in the PANSS or due
to overall somewhat lower repeated measurement reliability for positive compared with
negative symptoms, but see (Andreasen and Flaum, 1991).
The reliability estimates for the regression-based symptom conversions are in the fair to
excellent range (ICC29=0.65-0.97). However, many of the confidence interval (CI) lower
ends in the current study are in the poor range, likely due to the relatively small sample used
for ICC computation because CI inversely relates to the square root of the number of
subjects. The larger increases in mean squared prediction error between the original
regression and the validation regression for the positive compared with the negative
symptoms, suggests that the negative symptom conversion equations are highly predictive,
while the positive symptom conversion equations could be improved (see Table 1S in
Supplement S1). Compared to previously proposed methods (Lyne et al., 2011), the use of
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regression-based equations to convert symptom severity ratings between scales has the
distinct advantage of conserving the quantitative nature of the symptom ratings. The
conversion formulas are implemented at http://converteasy.org for ease of use by clinicians
and researchers alike.
It is important to note that the formulas provided in this study are based on the classical
scoring of the PANSS on a scale from 1-7. PANSS items should at least sometimes be
scored between 0-6 instead of 1-7, in particular when percent change scores need to be
calculated (Leucht et al., 2009; Thompson et al., 1994) and it has been argued that overall
the PANSS should be rescaled (Leucht et al., 2010; Obermeier et al., 2010; Thompson et al.,
1994); a similar rescaling has been argued for the Brief Psychiatric Rating Scale (Leucht et
al., 2007; Thompson et al., 1994). In cases where the PANSS is scored from 0-6, 7 points
should be added to the PANSS Positive subscore and to the PANSS Negative subscore prior
to conversion to another symptom score using the formulas provided in this manuscript.
Researchers must take care when conducting meta-analyses in this regard as the nature of
PANSS scoring is often not carefully described in the existing research literature; for review
see (Obermeier et al., 2011).
Though the study results are promising, caution is advised in using the reported equations
due to the need for additional validation and a number of inherent study limitations: (1) the
conversion equations were calculated for stable patients with moderate symptom severity
and it is unclear to what extent the findings generalize to clinical samples vastly different
from ours, such as patients with acute decompensation, including first-episode patients, and
patients whose severity of pathology is at the extremes of the clinical spectrum; (2) some of
the conversions have reliabilities (ICCs) in the fair range (0.50-0.70) and must obviously be
used with caution; (3) the ICCs are based on a relatively small sample resulting in relatively
large confidence intervals; (4) the ratings for each scale were performed by the same rater at
each site, which might result in a stronger correlation between the scales and higher
conversion reliabilities. Hence, further research is needed to determine the reliability of the
conversion equations for studies where scales are rated by different raters (Norman et al.,
1996); and (5) though raters were trained and their ratings compared with those from
experts, formal inter-rater reliability was not assessed quantitatively at study onset. Further,
in cases where the equations are employed to convert rating scale scores across different
research projects, comparative analyses within the individual scales may assist in overall
interpretation of results. Last, we advise against using the “homogenizing” effect of the
conversion process for the pooling of studies that are heterogeneous in aspects other than
their measurement scales.
Strengths of the study are that: (1) the SAPS, SANS, and PANSS symptom ratings occurred
during the same session allowing for maximal consistency with regard to clinician ratings on
the scales; (2) the symptom ratings were performed by highly-experienced raters who
underwent joint training sessions at the onset of the study; (3) the symptom ratings were
obtained from a relatively large community-based sample of patients with schizophrenia
(n=205) recruited at 7 sites across the country; and (4) conversion reliability was assessed
based on a subsample, independent of the one used to derive the regression equations.
In conclusion, the regression-based equations provided by this study may allow for
conversion between schizophrenia symptom severity as measures by the SANS/SAPS and
PANSS. Additional studies, preferably with large and diverse samples, should examine the
generalizability of the findings to other schizophrenia populations, including first-episode,
acute and more severely ill patients, and to instances where ratings are performed by
different raters. The conversion formulas provided by this study, as well as those achieved in
future studies, may aid in the comparison of medication efficacy studies, aid meta-analysis
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studies that plan to examine symptoms as moderator variables, and aid retrospective
combination of symptom data in multi-center data sharing projects that need to pool
symptom rating data from different rating scales.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Scatter Plot with Regression line (95% CI) for PANSS Positive Predicted by SAPS Total.
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Scatter Plot with Regression line (95% CI) for PANSS Negative Predicted by SANS Total.
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Age in Years 39.5 (11.6) 18-62
Age at Onset in Years 21.8 (7.5) 6-49
Duration of Illness in Years 17.7 (145) 1-49
NAART FSIQ 103 (9.5) 80-124
Subject Educationa 3.3 (0.9) 2-5
Highest Parental Educationa 2.4 (1.9) 0-9
PANSS Positive 15.7 (5.3) 7-33
PANSS Negative 14.9 (5.9) 7-39
PANSS General 28.6 (7.5) 16-48
PANSS Composite 0.77 (6.5) −19-19
PANSS Total 59.1 (15.4) 32-107
Marder Positive 17.8 (6.3) 8-41
Marder Negative 14.6 (6.4) 7-38
SANS
 Flat Affect 6.2 (6.8) 0-26
 Alogia 2.4 (3.2) 0-16
 Apathy 4.6 (3.3) 0-14
 Anhedonia 7.0 (5.1) 0-19
 Attention 2.7 (2.4) 0-9
SANS (composite) Total 23.0 (14.6) 0-70
SANS (global) Summary 7.8 (4.7) 0-74
SAPS
 Hallucinations 6.0 (6.1) 0-27
 Delusions 8.2 (7.8) 0-35
 Bizarre Behavior 1.3 (1.7) 0-8
 Thought Disorder 1.3 (1.7) 0-8
SAPS (composite) Total 16.8 (14.2) 0-74
SAPS (global) Summary 5.7 (3.7) 0-14
a
based on the Hollingstead Socioeconomic Status Scale (Hollingstead, 1975)
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Table 2






















Positive 1 0.32 0.71 0.30 0.78 0.34 0.92 0.29
PANSS
Negative 1 0.25xs* 0.84 0.34 0.82 0.32 0.93
SAPS
(composite)
Total 1 0.30 0.74 0.24xs* 0.71 0.25xs*
SANS
(composite)
Total 1 0.34 0.92 0.29 0.85
SAPS
(global)
Summary 1 0.38 0.76 0.28
SANS
(global)






p<0.001. For all other correlations p<0.0001
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Table 3
Intra-class Correlations (95% CI) Between Measured and Predicted Symptom Ratings Obtained with
Regression-Based Conversion Equations
Predicted Symptom Rating ICC (95% CI)
N=29
SAPS [composite] Total predicted by PANSS Positive* 0.65 (0.37 - 0.82)
SAPS [global] Summary predicted by PANSS Positive 0.72 (0.48 - 0.86)
SAPS [global] Summary predicted by SAPS [composite] Total score 0.68 (0.43 - 0.84)
PANSS Positive predicted by Marder Positive 0.97 (0.93 - 0.99)
SAPS [composite] Total predicted by Marder Positive 0.65 (0.37 - 0.82)
SAPS [global] Summary predicted by Marder Positive 0.66 (0.39 - 0.82)
SANS [global] Summary predicted by SANS [composite] Total score 0.91 (0.82 - 0.96)
SANS [composite] Total predicted by PANSS Negative 0.82 (0.66 - 0.91)
SANS [global] Summary predicted by PANSS Negative 0.78 (0.58 - 0.89)
PANSS Negative predicted by Marder Negative 0.92 (0.84 - 0.96)
SANS [composite] Total predicted by Marder Negative 0.66 (0.40 - 0.82)
SANS [global] Summary predicted by Marder Negative 0.79 (0.61 -0.90)
*
Note that the ICCs for the vice versa predictions (e.g., PANSS Positive predicted by SAPS [composite] Total are equivalent.
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